Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...

Brain-meningeal immunity is increasingly recognized as a central player in the complex network of interactions within the central nervous system (CNS).

“清华大学具身智能脑机接口与微纳机器人实验室” ...

FLORHAM PARK, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of ...

The "Central Nervous System Therapeutics Market - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering. The global market for Central Nervous System Therapeutics was ...

The global Central Nervous System (CNS) therapeutic market is projected to reach US$ 235.87 billion by 2033. This growth is ...

Relationship between efficacy of phase I/II drug ispinesib in medulloblastoma, molecular subtypes, and p53-mutant status. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This ...

A central nervous system (CNS) tumor has prompted the FDA to place clinical holds on two Regenxbio gene therapies, including ...

Iopofosine I 131 Active in Treating Malignancies in the Brain; Confirmed Response in CNS Lymphoma Provides Additional Validation for Continued Development of Iopofosine in Multiple CNS Malignancies ...

The Global Central Nervous System Therapeutics Market is poised for growth driven by an aging population and heightened ...